Clinical Trial Update: Sorafenib Treatment in Non-Small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating sorafenib for non-small cell lung cancer after failure of EGFR tyrosine kinase inhibitors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: Chinese Society of Lung Cancer | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED